Vasculopathy-related cutaneous lesions and intrahepatic cholestasis as synchronous manifestations in a COVID-19 patient; a case report
Gastroenterology and Hepatology from Bed to Bench,
Vol. 13 No. 4 (2020),
20 September 2020
,
Page 400-404
https://doi.org/10.22037/ghfbb.v13i4.2043
Abstract
Today, COVID-19 pneumonia causes global concern. The World Health Organization (WHO) has reported many mortalities from this disease all around the world. Therefore, recognizing new cases of COVID-19 is crucial during this pandemic. Many studies have shown that COVID-19 has a broad spectrum of signs and symptoms, including GI and cutaneous manifestations. Previous studies have reported liver enzyme changes as well as diarrhea as a common GI manifestation of COVID-19. However, there are few reports about COVID-19 synchronous cutaneous and liver involvement. Additionally, there are few reports about intrahepatic cholestasis in COVID-19 patients. In this article, a confirmed case of COVID-19 with vasculopathy-related cutaneous manifestation and liver cholestasis is reported. A 67-year-old Iranian woman was admitted to Taleghani Hospital with epigastric pain, vomiting, anosmia, rising liver enzyme levels, fever, itching, and skin rashes. Skin and liver biopsies were performed during the patient’s admission; the results suggested vasculopathy-related cutaneous lesion and liver cholestasis. Plasmapheresis was initiated and all manifestations disappeared after treatment. All atypical presentations, including cutaneous lesions and liver manifestations, should be considered as COVID-19 and evaluated.
Keywords: COVID-19, cholestasis, liver, vasculitis, cutaneous lesion, skin
(Please cite as: Sadeghi A, Dooghaie Moghadam A, Eslami P, Pirsalehi A, Salari S , Roshandel E. Vasculopathy-related Cutaneous Lesions and Intrahepatic Cholestasis as Synchronous Manifestations in a COVID-19 Patient: a Case Report. Gastroenterol Hepatol Bed Bench 2020;13(4):400-404).
- COVID-19, cholestasis, liver, vasculitis, cutaneous lesion, skin
How to Cite
References
Organization WH. Coronavirus disease(COVID-19)Situation Report – 182 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200720-covid-19-sitrep-182.pdf?sfvrsn=60aabc5c_2.
Torkian P, Ramezani N, Kiani P, Bax MR, Akhlaghpoor S. Common CT Findings of Novel Coronavirus Disease 2019 (COVID-19): A Case Series. Cureus 2020;3.
Singhal T. A Review of Coronavirus Disease-2019 (COVID-19).Indian J Pediatr 2020;4:281-6.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;18:1708-20.
Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. J Am Acad Dermatol 2020;83:e57-60.
Hormati A, Shahhamzeh A, Afifian M, Khodadust F, Ahmadpour S. Can COVID-19 present unusual GI symptoms. J Microbiol Immunol Infect 2020;3:182-3.
Moazzami B, Razavi-Khorasani N, Dooghaie-Moghadam A, Farokhi E, Rezaei N. COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being. J Clin Virol 2020;126:104345.
Prevention CfDCa. symptoms 2020 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
Dooghaie-Moghadam A, Eslami P, Razavi-Khorasani N, Moazzami B, Mousavizadeh M, Zali MR, et al. The Impacts of the COVID-19 Pandemic on Liver Transplant Patients; Time to Change the Priorities. Arch Iran Med 2020;7:507-8.
Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 2020;6:656-65.
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020;34:e212-3.
Castelnovo L, Capelli F, Tamburello A, Maria-Faggioli P, Mazzone A. Symmetric cutaneous vasculitis in COVID-19 pneumonia. J Eur Acad Dermatol Venereol 2020;34:e362-3.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol 2020;214.
Qureshi WA. Intrahepatic cholestatic syndromes: pathogenesis, clinical features and management. Dig Dis 1999;1:49.
Li J, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. J Clin Transl Hepatol 2020;1:13-7.
Delemos AS, Friedman LS. Systemic causes of cholestasis. Clin Liver Dis 2013;2:301-17.
Omrani-Nava V, Maleki I, Ahmadi A, Moosazadeh M, Hedayatizadeh-Omran A, Roozbeh F, et al. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. Hepat Mon 2020;4:e103179.
Al-Azzawi H, Patel R, Sood G, Kapoor S. Plasmapheresis for Refractory Pruritus due to Drug-Induced Cholestasis. Case Rep Gastroenterol 2017;3:814-8.
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care 2020;1:128.
.
- Abstract Viewed: 35 times
- PDF Downloaded: 27 times